Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, Mark J., Lyke, Kirsten E., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, Neuzil, Kathleen, Raabe, Vanessa, Bailey, Ruth, Swanson, Kena A., Li, Ping, Koury, Kenneth, Kalina, Warren, Cooper, David, Fontes-Garfias, Camila, Shi, Pei-Yong, Türeci, Ӧzlem, Tompkins, Kristin R., Walsh, Edward E., Frenck, Robert, Falsey, Ann R., Dormitzer, Philip R., Gruber, William C., Şahin, Uğur, Jansen, Kathrin U.·2020·Nature
DOI 10.1101/2020.06.30.20142570

Cited by (1,004)

Items 101–200 of 1,004

  1. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
    Christine D. Palmer, Amy Rappaport, Matthew J. Davis, Meghan G. Hart, Ciaran D. Scallan, Sue‐Jean Hong, Leonid Gitlin, Lauren D. Kraemer, Sonia Kounlavouth, Aaron Yang et al. · 2022 · Nature Medicine
  2. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
    Daniel Martínez-Flores, Jesús Zepeda–Cervantes, Adolfo Cruz-Reséndiz, Sergio Aguirre‐Sampieri, Alicia Sampieri, Luis A. Vaca · 2021 · Frontiers in Immunology
  3. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
    Laurence Chu, Roderick A. McPhee, Wenmei Huang, Hamilton Bennett, Rolando Pajón, Biliana Nestorova, Brett A. Leav · 2021 · Vaccine
  4. Vaccines for COVID-19
    John S. Tregoning, E S Brown, Hannah M. Cheeseman, Katie E. Flight, Sophie L. Higham, N-M Lemm, Benjamin F. Pierce, David C. Stirling, Ziyin Wang, Katrina M. Pollock · 2020 · Clinical & Experimental Immunology
  5. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research
    Suzannah J. Rihn, Andres Merits, Siddharth Bakshi, Matthew L. Turnbull, Arthur Wickenhagen, Akira J. T. Alexander, Carla Baillie, Benjamin Brennan, Fiona Brown, Kirstyn Brunker et al. · 2021 · PLoS Biology
  6. Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer
    Jilian R. Melamed, Saigopalakrishna S. Yerneni, Mariah Lynn Arral, Samuel T. LoPresti, Namit Chaudhary, Anuradha Sehrawat, Hiromi Muramatsu, Mohamad‐Gabriel Alameh, Norbert Pardi, Drew Weissman et al. · 2023 · Science Advances
  7. Non-viral COVID-19 vaccine delivery systems
    Kyung Soo Park, Xiaoqi Sun, Marisa E. Aikins, James Jaehyun Moon · 2020 · Advanced Drug Delivery Reviews
  8. Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design
    Qi Qiao, Xiong Liu, Ting Yang, Kexin Cui, Li Kong, Conglian Yang, Zhiping Zhang · 2021 · Acta Pharmaceutica Sinica B
  9. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial
    Aldrich, Cassandra, Leroux–Roels, Isabel, Huang, Katell Bidet, Bica, Mihai Alexandru, Loeliger, Edde, Schoenborn-Kellenberger, Oliver, Walz, Lisa, Leroux-Roels, Geert, von Sonnenburg, Frank, Oostvogels, Lidia · 2021 · Vaccine
  10. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
    Ana Cristina de Medeiros Ribeiro, Nádia Emi Aikawa, Carla Gonçalves Schahin Saad, Emily Figueiredo Neves Yuki, Tatiana do Nascimento Pedrosa, Solange Regina Giglioli Fusco, Priscila Tagliaferro Rojo, Rosa Maria Rodrigues Pereira, Samuel Katsuyuki Shinjo, Danieli C. O. Andrade et al. · 2021 · Nature Medicine
  11. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
    Zezhong Liu, Wei Xu, Shuai Xia, Chenjian Gu, Xinling Wang, Qian Wang, Jie Zhou, Yanling Wu, Xia Cai, Di Qu et al. · 2020 · Signal Transduction and Targeted Therapy
  12. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection
    Raveen Rathnasinghe, Shirin Strohmeier, Fatima Amanat, Virginia Gillespie, Florian Krammer, Adolfo García‐Sastre, Lynda Coughlan, Michael Schotsaert, Melissa B. Uccellini · 2020 · Emerging Microbes & Infections
  13. Modelling optimal vaccination strategy for SARS-CoV-2 in the UK
    Sam Moore, Edward M. Hill, Louise Dyson, Michael J. Tildesley, Matt J. Keeling · 2021 · PLoS Computational Biology
  14. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273
    Teo, Shyh Poh · 2022 · Journal of Pharmacy Practice
  15. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
    Israelow, Benjamin, Mao, Tianyang, Klein, Jonathan, Song, Eric, Menasche, Bridget, Omer, Saad B., Iwasaki, Akiko · 2021 · Science Immunology
  16. Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
    Mounzer Agha, Maggie Blake, Charles Chilleo, Alan H. Wells, Ghady Haidar · 2021 · Open Forum Infectious Diseases
  17. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
    Israelow, Benjamin, Mao, Tianyang, Klein, Jonathan, Song, Eric, Menasche, Bridget, Omer, Saad B., Iwasaki, Akiko · 2021
  18. Structural basis for broad coronavirus neutralization
    Maximilian M. Sauer, M. Alejandra Tortorici, Young‐Jun Park, Alexandra C. Walls, Leah J. Homad, Oliver J. Acton, John E. Bowen, Chunyan Wang, Xiaoli Xiong, Willem de van der Schueren et al. · 2021 · Nature Structural & Molecular Biology
  19. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system
    Colin Pawlowski, Patrick J. Lenehan, Arjun Puranik, Vineet Agarwal, AJ Venkatakrishnan, Michiel J.M. Niesen, John Charles O’Horo, Abinash Virk, Melanie D. Swift, Andrew D. Badley et al. · 2021 · Med
  20. Nanotechnology for modern medicine: next step towards clinical translation
    Shrey Sindhwani, Warren C. W. Chan · 2021 · Journal of Internal Medicine
  21. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV‑2 in Mice
    Abigail E. Powell, Kaiming Zhang, Mrinmoy Sanyal, Shaogeng Tang, Payton A. B. Weidenbacher, Shanshan Li, Tho D. Pham, John E. Pak, Wah Chiu, Peter S. Kim · 2021 · ACS Central Science
  22. Clinical and immunological effects of mRNA vaccines in malignant diseases
    Annkristin Heine, Stefan Juranek, Peter Brossart · 2021 · Molecular Cancer
  23. Engineering SARS-CoV-2 using a reverse genetic system
    Xuping Xie, Kumari G. Lokugamage, Xianwen Zhang, Michelle N. Vu, Antonio E. Muruato, Vineet D. Menachery, Pei‐Yong Shi · 2021 · Nature Protocols
  24. Nanovaccines: A game changing approach in the fight against infectious diseases
    Priyanka, Mai Abdel Haleem Abusalah, Hitesh Chopra, Abhilasha Sharma, Suhad Asad Mustafa, Om Prakash Choudhary, Manish Kumar Sharma, Manish K. Dhawan, Rajiv Khosla, Aanchal Loshali et al. · 2023 · Biomedicine & Pharmacotherapy
  25. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line
    Markus Aldén, Francisko Olofsson Falla, Daowei Yang, Mohammad Barghouth, Cheng Luan, Magnus Rasmussen, Yang Z. De Marinis · 2022 · Current Issues in Molecular Biology
  26. Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies
    Jonah Clegg, Elisabetta Soldaini, Rachel M. McLoughlin, Stephen F. Rittenhouse, Fábio Bagnoli, Sanjay Kumar Phogat · 2021 · Frontiers in Immunology
  27. A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic
    Chris R. Triggle, Devendra Bansal, Hong Ding, Md. Mazharul Islam, Elmoubasher Farag, Hamad Abdel Hadi, Ali A. Sultan · 2021 · Frontiers in Immunology
  28. Zwitterionic Phospholipidation of Cationic Polymers Facilitates Systemic mRNA Delivery to Spleen and Lymph Nodes
    Shuai Liu, Xu Wang, Xueliang Yu, Qiang Cheng, Lindsay T. Johnson, Sumanta Chatterjee, Di Zhang, Sang M. Lee, Yehui Sun, Ting‐Chih Lin et al. · 2021 · Journal of the American Chemical Society
  29. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs
    Stephanie Seneff, Greg Nigh, Anthony M. Kyriakopoulos, Peter Andrew McCullough · 2022 · Food and Chemical Toxicology
  30. Learning from the past: development of safe and effective COVID-19 vaccines
    Shan Su, Lanying Du, Shibo Jiang · 2020 · Nature Reviews Microbiology
  31. Recent Advancement in mRNA Vaccine Development and Applications
    Nojoud AL Fayez, Majed Saeed Nassar, Abdullah Awad Alshehri, Meshal K. Alnefaie, Fahad A. Almughem, Bayan Y. Alshehri, Abdullah O. Alawad, Essam A. Tawfik · 2023 · Pharmaceutics
  32. SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA
    Amanda Jack, Luke S. Ferro, Michael J. Trnka, Eddie Wehri, Amrut Nadgir, Xammy Huu Nguyenla, Douglas Fox, Katelyn Costa, Sarah A. Stanley, Julia Schaletzky et al. · 2021 · PLoS Biology
  33. Immunity to SARS‐CoV‐2 induced by infection or vaccination
    Xaquín Castro Dopico, Sebastian Ols, Karin Loré, Gunilla B. Karlsson Hedestam · 2021 · Journal of Internal Medicine
  34. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
    Rauch, Susanne, Roth, Nicole, Schwendt, Kim, Fotin-Mleczek, Mariola, Mueller, Stefan O., Petsch, Benjamin · 2021 · npj Vaccines
  35. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients
    Clément Danthu, Sébastien Hantz, Arthur Dahlem, Marion Duval, Bacary Bâ, Manon Guibbert, Zhour El Ouafi, Séverine Ponsard, Insaf Berrahal, Jean-Michel Achard et al. · 2021 · Journal of the American Society of Nephrology
  36. Approved Nanomedicine against Diseases
    Yuanchao Jia, Yuxin Jiang, Yonglong He, Wanting Zhang, Jiahui Zou, Kosheli Thapa Magar, Hamza Boucetta, Chao Teng, Wei He · 2023 · Pharmaceutics
  37. Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand
    Zoltán Kis, Cleo Kontoravdi, Robin J. Shattock, Nilay Shah · 2020 · Vaccines
  38. The Past, Present, and Future of Non-Viral CAR T Cells
    Alex Moretti, Marianna Ponzo, Charles A. Nicolette, Irina Y. Tcherepanova, Andrea Biondi, Chiara Francesca Magnani · 2022 · Frontiers in Immunology
  39. The transmission modes and sources of COVID-19: A systematic review
    Heshu Sulaiman Rahman, Masrur S. Aziz, Ridha Hassan Hussein, Hemn Hassan Othman, Shirwan Hama Salih Omer, Eman Star Khalid, Nusayba Abdulrazaq Abdulrahman, Kawa Amin, Rasedee Abdullah · 2020 · International Journal of Surgery Open
  40. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects
    Sarah Wheeler, Galina V. Shurin, Mary Yost, Adam Anderson, Lisa Pinto, Alan H. Wells, Michael R. Shurin · 2021 · Microbiology Spectrum
  41. Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans
    Cagigi, Alberto, Loré, Karin · 2021 · Vaccines
  42. COVID-19 and cellular senescence
    Schmitt, Clemens A., Tchkonia, Tamar, Niedernhofer, Laura J., Robbins, Paul D., Kirkland, James L., Lee, Soyoung · 2023 · Nature Reviews Immunology
  43. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer
    Sidse Ehmsen, Anders Asmussen, Stefan Starup Jeppesen, Anna Christine Nilsson, Sabina Østerlev, Hanne Vestergaard, Ulrik Stenz Justesen, Işık Somuncu Johansen, Henrik Frederiksen, Henrik J. Ditzel · 2021 · Cancer Cell
  44. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
    Kimberly Risma, Kathryn M. Edwards, Donna S. Hummell, Frédéric F. Little, Allison Eaddy Norton, Amy Polen Stallings, Robert A. Wood, Joshua D. Milner · 2021 · Journal of Allergy and Clinical Immunology
  45. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
    Bogdan Doroftei, Alin Stelian Ciobica, Ovidiu‐Dumitru Ilie, Radu Maftei, Ciprian Gavrilă Ilea · 2021 · Diagnostics
  46. Critical Review of the Evolution of Extracellular Vesicles’ Knowledge: From 1946 to Today
    Erica Bazzan, Mariaenrica Tinè, Alvise Casara, Davide Biondini, Umberto Semenzato, Elisabetta Cocconcelli, Elisabetta Balestro, Marco Damin, Claudia Maria Radu, Graziella Turato et al. · 2021 · International Journal of Molecular Sciences
  47. “COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment”
    Girish Gilly Munavalli, Rachel Guthridge, Siri Knutsen-Larson, Amy Brodsky, Ethan J Matthew, Marina Landau · 2021 · Archives of Dermatological Research
  48. Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs
    Weingarten-Gabbay, Shira, Klaeger, Susan, Sarkizova, Siranush, Pearlman, Leah R., Chen, Da-Yuan, Gallagher, Kathleen M.E., Bauer, Matthew R., Taylor, Hannah B., Dunn, W. Augustine, Tarr, Christina et al. · 2021 · Cell
  49. Current Prevention of COVID-19: Natural Products and Herbal Medicine
    Junqing Huang, Gabriel Tao, Jingwen Liu, Junming Cai, Zhongyu Huang, Jiaxu Chen · 2020 · Frontiers in Pharmacology
  50. Therapeutic induction of antigen-specific immune tolerance
    Jessica E. Kenison, Nikolas A. Stevens, Francisco Javier Quintana · 2023 · Nature reviews. Immunology
  51. Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines
    Despo Chatzikleanthous, Derek T. O’Hagan, Roberto Adamo · 2021 · Molecular Pharmaceutics
  52. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
    Musha Chen, Yue Yuan, Yiguo Zhou, Zhaomin Deng, Jin Zhao, Fengling Feng, Huachun Zou, Caijun Sun · 2021 · Infectious Diseases of Poverty
  53. The use of RNA-based treatments in the field of cancer immunotherapy
    Mohammad Chehelgerdi, Matin Chehelgerdi · 2023 · Molecular Cancer
  54. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
    Tianshu Xiao, Jianming Lü, Jun Zhang, Rebecca I. Johnson, Lindsay G. A. McKay, Nadia Storm, Christy L. Lavine, Hanqin Peng, Yongfei Cai, Sophia Rits‐Volloch et al. · 2021 · Nature Structural & Molecular Biology
  55. Omics-Driven Biotechnology for Industrial Applications
    Bashar Amer, Edward E. K. Baidoo · 2021 · Frontiers in Bioengineering and Biotechnology
  56. Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
    Radwa Ewaisha, Karen S. Anderson · 2023 · Frontiers in Bioengineering and Biotechnology
  57. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
    Harry Kleanthous, Judith M. Silverman, Karen W. Makar, In-Kyu Yoon, Nicholas M. Jackson, David W. Vaughn · 2021 · npj Vaccines
  58. A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
    Vogel, Annette B., Kanevsky, Isis, Che, Ye, Swanson, Kena A., Muik, Alexander, Vormehr, Mathias, Kranz, Lena M., Walzer, Kerstin C., Hein, Stephanie, Güler, Alptekin et al. · 2020
  59. Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
    Matthias Becker, Alex Dulovic, Daniel Junker, Natalia Ruétalo, Philipp D. Kaiser, Yudi Tatiana Pinilla, Constanze Heinzel, Julia Häring, Bjoern Traenkle, Teresa R. Wagner et al. · 2021 · Nature Communications
  60. Fast microwave heating-based one-step synthesis of DNA and RNA modified gold nanoparticles
    Mengqi Huang, Erhu Xiong, Yan Wang, Menglu Hu, Huahua Yue, Tian Tian, Debin Zhu, Hong Shi Liu, Xiaoming Zhou · 2022 · Nature Communications
  61. TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer
    Zhangli Su, Ida Monshaugen, Briana Wilson, Fengbin Wang, Arne Klungland, Rune Ougland, Anindya Dutta · 2022 · Nature Communications
  62. Efforts at COVID-19 Vaccine Development: Challenges and Successes
    Azizul Haque, Anudeep B. Pant · 2020 · Vaccines
  63. Efficacy and safety of COVID-19 vaccines: a systematic review.
    Kai Xing, Xiao-Yan Tu, Miao Liu, Zhang-Wu Liang, Jiang-Nan Chen, Jiao Jiao Li, Li-Guo Jiang, Fu-Qiang Xing, Yi Jiang · 2021 · PubMed Central
  64. Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease
    Juliana C. Ferreira, Samar Fadl, Adrian J. Villanueva, Wael M. Rabeh · 2021 · Frontiers in Chemistry
  65. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
    Li, Jingxin, Hui, Aimin, Zhang, Xiang, Yang, Yumei, Tang, Rong, Ye, Huayue, Ji, Ruiru, Lin, Mei, Zhu, Zhongkui, Türeci, Özlem et al. · 2021 · Nature Medicine
  66. Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics
    Xiao Tan, Justin H. Letendre, James J. Collins, Wilson W. Wong · 2021 · Cell
  67. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials
    Zhipeng Yan, Ming Yang, Ching‐Lung Lai · 2021 · Pharmaceuticals
  68. Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines
    Ger T. Rijkers, Nynke Weterings, Andrés Obregón‐Henao, Tara Dutt, Taru S. Dutt, Frans J. van Overveld, Marcela I. Henao-Tamayo · 2021 · Vaccines
  69. Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics
    Kai K. Ewert, Pablo Scodeller, Lorena Simón‐Gracia, Victoria M. Steffes, Emily A. Wonder, Tambet Teesalu, Cyrus R. Safinya · 2021 · Pharmaceutics
  70. T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses
    Elahe Aleebrahim‐Dehkordi, Bahareh Molavi, Melika Mokhtari, Niloofar Deravi, Mobina Fathi, Tara Fazel, Mehdi Mohebalizadeh, Pooneh Koochaki, Parnian Shobeiri, Ali Hasanpour Dehkordi · 2021 · Transplant Immunology
  71. Current Status and Future Perspectives on MRNA Drug Manufacturing
    Cameron Webb, Shell Y. Ip, Nuthan Vikas Bathula, Petya G. Popova, Shekinah K. V. Soriano, Bao-Han Ly, Burcu Eryilmaz, Viet Anh Nguyen Huu, Richard Broadhead, Martin Rabel et al. · 2022 · Molecular Pharmaceutics
  72. The immunostimulatory nature of mRNA lipid nanoparticles
    Preeti Sharma, Daniek Hoorn, Anjaiah Aitha, Dor Breier, Dan Peer · 2024 · Advanced Drug Delivery Reviews
  73. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity
    Yang, Ren, Deng, Yao, Huang, Baoying, Huang, Lei, Lin, Ang, Li, Yuhua, Wang, Wenling, Liu, Jingjing, Lu, Shuaiyao, Zhan, Zhenzhen et al. · 2021 · Signal Transduction and Targeted Therapy
  74. COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology
    Hyun Jee Han, Chinekwu Sherridan Nwagwu, Obumneme Benneth Anyim, Chinedu Ekweremadu, San Kim · 2020 · International Immunopharmacology
  75. Escaping the endosome: assessing cellular trafficking mechanisms of non-viral vehicles
    Emily Xu, W. Mark Saltzman, Alexandra S. Piotrowski-Daspit · 2021 · Journal of Controlled Release
  76. Lipid carriers for mRNA delivery
    Wanting Zhang, Yuxin Jiang, Yonglong He, Hamza Boucetta, Jun Wu, Zhongjian Chen, Wei He · 2022 · Acta Pharmaceutica Sinica B
  77. Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies
    Pu-Sheng Wei, Nagasri Thota, Greshma John, Evelyn Chang, Sunjae Lee, Yuanjun Wang, Zitao Ma, Yu-Hsuan Tsai, Kuo‐Ching Mei · 2024 · Journal of Controlled Release
  78. Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
    Jéromine Klingler, Svenja Weiß, Vincenza Itri, Xiaomei Liu, Kasopefoluwa Y. Oguntuyo, Christian S. Stevens, Satoshi Ikegame, Chuan-Tien Hung, Gospel M Enyindah-Asonye, Fatima Amanat et al. · 2020 · The Journal of Infectious Diseases
  79. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
    Szu-Min Hsieh, Ming-Che Liu, Yen-Hsu Chen, Wen-Sen Lee, Shinn-Jang Hwang, Shu-Hsing Cheng, Wen-Chien Ko, Kao-Pin Hwang, Ning-Chi Wang, Yu-Lin Lee et al. · 2021 · The Lancet Respiratory Medicine
  80. Development and Delivery Systems of mRNA Vaccines
    Yongjun Liang, Liping Huang, Tiancai Liu · 2021 · Frontiers in Bioengineering and Biotechnology
  81. Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: An exploratory clinical trial
    Xiaowei Xu, Wanli Jiang, Lijun Chen, Zhenyu Xu, Qiang Zhang, Mengfei Zhu, Peng Ye, Hang Li, Liang Yu, Xiaoyang Zhou et al. · 2021 · Clinical and Translational Medicine
  82. SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review
    Hadis Fathizadeh, Saman Afshar, Mahmood Reza Masoudi, Pourya Gholizadeh, Mohammad Asgharzadeh, Khudaverdi Ganbarov, Şükran Köse, Mehdi Yousefi, Hossein Samadi Kafil · 2021 · International Journal of Biological Macromolecules
  83. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
    Zhuoya Deng, Yuying Tian, Jianxun Song, Guangwen An, Penghui Yang · 2022 · Frontiers in Immunology
  84. Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation
    Musa Rakhimovich Khaitov, Alexandra A. Nikonova, Igor P. Shilovskiy, Ksenia V. Kozhikhova, И.А. Кофиади, L.I. Vishniakova, Alexander Nikolskii, Pia Gattinger, V.I. Kovchina, E.D. Barvinskaia et al. · 2021 · Allergy
  85. Varicella Zoster Virus Reactivation Following COVID-19 Vaccination: A Systematic Review of Case Reports
    Konstantinos Katsikas Triantafyllidis, Panagiotis Giannos, Imran Tariq-Mian, George Kyrtsonis, Konstantinos S. Kechagias · 2021 · Vaccines
  86. Influenza vaccines: Past, present, and future
    Yun Hee Kim, Kee‐Jong Hong, Hun Kim, Jae‐Hwan Nam · 2021 · Reviews in Medical Virology
  87. The race to a COVID-19 vaccine: opportunities and challenges in development and distribution
    Rodrigo M Burgos, Melissa E. Badowski, Emily N. Drwiega, Samaneh Ghassemi, Nikki Griffith, Fischer Herald, Mikayla Johnson, Renata O. Smith, Sarah M. Michienzi · 2021 · Drugs in Context
  88. Single-cell epigenomic landscape of peripheral immune cells reveals establishment of trained immunity in individuals convalescing from COVID-19
    Maojun You, Liang Chen, Dawei Zhang, Peng Zhao, Zhu Chen, Enqiang Qin, Yanan Gao, Mark M. Davis, Pengyuan Yang · 2021 · Nature Cell Biology
  89. Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge
    Rodney Glenn King, Aarón Silva-Sánchez, Jessica N. Peel, Davide Botta, Alexandria M. Dickson, Amelia K. Pinto, Selene Meza‐Perez, S. Rameeza Allie, Michael D. Schultz, Mingyong Liu et al. · 2021 · Vaccines
  90. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
    Paul Goepfert, Bo Fu, Anne-Laure Chabanon, Matthew I Bonaparte, Matthew Davis, Brandon J. Essink, Ian Frank, Owen Haney, Helene Janosczyk, Michael C. Keefer et al. · 2021 · The Lancet Infectious Diseases
  91. Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers
    Dapeng Zhang, Elena N. Atochina‐Vasserman, Devendra S. Maurya, Matthew Liu, Qi Xiao, Juncheng Lu, George Lauri, Nathan A. Ona, Erin K. Reagan, Houping Ni et al. · 2021 · Journal of the American Chemical Society
  92. Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals
    Marie I. Samanovic, Amber R. Cornelius, Sophie L. Gray-Gaillard, Joseph R. Allen, Trishala Karmacharya, Jimmy P. Wilson, Sara Hyman, Michael Tuen, Sergei B. Koralov, Mark J. Mulligan et al. · 2022 · Science Translational Medicine
  93. Approaches and Challenges in SARS-CoV-2 Vaccine Development
    Dagotto, Gabriel, Yu, Jingyou, Barouch, Dan H. · 2020 · Cell Host & Microbe
  94. Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)
    2022
  95. Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
    Mattia Tiboni, Luca Casettari, Lisbeth Illum · 2021 · International Journal of Pharmaceutics
  96. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses
    Clayton J. Wollner, Michelle Richner, Mariah Hassert, Amelia K. Pinto, James D. Brien, Justin M. Richner · 2021 · Journal of Virology
  97. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
    Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Daniel Shitu Mekonnen, Abtie Abebaw, Melese Getachew, Tengchuan Jin · 2021 · Seminars in Immunology
  98. Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications
    Kai Yuan Leong, Seng Kong Tham, Chit Laa Poh · 2025 · Virology Journal
  99. Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis
    2021
  100. Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity
    Guangna Liu, Motao Zhu, Xiao Zhao, Guangjun Nie · 2021 · Advanced Drug Delivery Reviews